BeiGene is a company that makes medicine to help people with sicknesses. They are trying to grow their business by making more medicines and selling them in different countries. Because they are growing, they need more workers and money to build new places where they can do research. People who own part of the company (shares) think it's going well so far, but they want to see if BeiGene can make even better medicines that sell very well. They will keep an eye on how much money BeiGene spends and how many new workers they hire. Read from source...

1. The title of the article is misleading, as it implies that BeiGene's aggressive expansion has a negative impact on its revenue, while the rest of the article provides evidence that the company is growing and investing in R&D despite market challenges. A more accurate title would be something like "BeiGene's Aggressive Expansion Fuels Growth and Innovation".
2. The article compares BeiGene's P/S ratio to Shanghai Junshi Biosciences, without providing any context or explanation for why this comparison is relevant or meaningful. A more informative comparison would be to other biotech companies in the same sector or with similar business models.
3. The article mentions BeiGene's confidence in its outlook and ability to raise new financing, but does not provide any data or examples to support this claim. It also does not discuss the risks or challenges that BeiGene faces in developing new drugs or entering new markets, which could affect its future performance and profitability.
4. The article uses words like "unwavering", "success", "content", and "gage" to convey a positive tone and attitude towards BeiGene, without providing any objective evidence or analysis. These words suggest that the author has a favorable bias towards the company, which could influence the reader's perception of its performance and prospects.

- Buy BeiGene shares for long-term growth potential, as the company continues to aggressively expand its global presence and R&D capabilities. The recent revenue jolt shows that BeiGene has a strong demand for its products and can generate significant cash flows from sales. However, investors should be aware of the following risks:
- BeiGene operates in a highly competitive industry, with many other players developing similar drugs or biosimilars. The company will need to continue innovating and differentiating itself from its rivals to maintain market share and pricing power.
- BeiGene's expansion strategy requires significant capital expenditures, which may impact its profitability and cash flow in the short term. The company also has a high debt burden, which could limit its financial flexibility and ability to pursue strategic acquisitions or partnerships.
- BeiGene's success depends largely on the clinical outcomes of its drugs, especially Zanubrutinib, which is currently undergoing phase 3 trials for various indications. If the drug fails to meet expectations or faces regulatory hurdles, it could negatively impact the company's reputation and stock price.